when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Hepatology · news · pharmadog

← back to Hepatology

News · Hepatology

122 stories

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 15, 26FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetesfda press

Jun 11, 26HHS responds coolly to paper on alcohol riskstat

Jun 9, 26Gilead and Merck’s latest trial success and flopstat

Jun 9, 26Alcohol study discarded by Trump officials is published in scientific journalstat

Jun 8, 26STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trialsstat

Jun 8, 26City banks nearly $100M for next-gen RNAi drugsbiopharma dive

Jun 8, 26City Therapeutics gets $99M to gather data on three RNAi medicinesendpoints

Jun 8, 26GSK inks multi-target pact with Engitix; Sangamo considers strategic optionsendpoints

Jun 7, 26STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugstat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

Jun 4, 26Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storystat

Jun 3, 26NewLimit’s $435M megaround; Lilly’s busy dealmaking weekbiopharma dive

Jun 3, 26Is the military fueling eating disorders?stat

Jun 2, 26STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trialstat

Jun 1, 26#ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroupendpoints

May 29, 26Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’stat

May 28, 26GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’biopharma dive

May 22, 26FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infectionfda press

May 19, 26STAT+: 1 in 8 women drink during pregnancy. Experts dread the consequencesstat

May 19, 26Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survivestat

May 18, 26Amgen stands by rare disease drug Tavneos amid Japan liver toxicity reportendpoints

May 15, 26Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placestat

May 14, 26STAT investigates the epidemic killing 178,000 Americans a yearstat

May 14, 26With new data, Regenxbio to seek FDA approval of Duchenne gene therapybiopharma dive

May 14, 26STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submissionstat

May 14, 26STAT+: Treatment for alcohol addiction is undergoing a seismic shift. Many say it’s overduestat

May 13, 26Patient Selection for Radiopharmaceuticals in Metastatic Castration-Resistant Prostate Canceronclive

May 13, 26Extreme heat is worsening faster for Black Americansstat

← prevpage 3 of 5next →